Evofem Biosciences, Inc. (EVFM) Stock Price Quote, News &…

Summary

Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.

Website

www.evofem.com

Location

San Diego, CA, US

Phone858 550 1900

Employees29

CEOSaundra Pelletier

Sector

Health Care

Industry

Pharmaceuticals

IPO DateNov 20, 2014

Ask AI

Company overview

Business model, segments, and competition.

Peer comparison

Metrics vs closest competitors.

Guidance & outlook

Forward guidance and assumptions.

Bull vs bear case

Upside drivers and key risks.

Valuation snapshot

Multiples vs history and peers.

Competitive moat

Defensibility and market position.

Management track record

Leadership and capital allocation history.

How it makes money

A short diagram of the business model.

Latest Documents

Mentions in Filings

… lients, including a not-for-profit and an early-stage artificial intelligence and data-driven health and wellness tracker. From February 2022 to December 2022, Ms. Fedasz served as Head of Business Development for Evofem Biosciences, a Nasdaq-listed public biotech company developing innovative products for women's health. From August 2019 to October 2021, Ms. Fedasz served in various positions of increasing responsibility, including Chief Fina …
Onconetix, Inc.Evofem Biosciences, Inc.·ARS - Annual report to security holders·FY25·16 Oct
… clients, including a not-for-profit and an early-stage artificial intelligence and data-driven health and wellness tracker. From February 2022 to December 2022, Ms. Fedasz served as Head of Business Development for Evofem Biosciences, a Nasdaq-listed public biotech company developing innovative products for women’s health. From August 2019 to October 2021, Ms. Fedasz served in various positions of increasing responsibility, including Chief Finan …
Onconetix, Inc.Evofem Biosciences, Inc.·DEF 14A - DEFINITIVE PROXY STATEMENT·Q4 26·7 Oct
… diverse range of experience, having worked in various industries, including the life sciences industry for the past 17 years. From 2015 to 2023, Mr. File was the Chief Financial Officer and Corporate Secretary of Evofem Biosciences, Inc., a women's health company that developed and commercialized Phexxi®, a nonhormonal contraceptive for women. While at Evofem he helped bring the company public through a reverse merger and was responsible for over …
Lite Strategy, Inc.Evofem Biosciences, Inc.·10-K - Annual report FY 2026·FY26·28 Sep
… DAQ: OVAS) | | 5 | | 10/12/2018 | Aravive Biologics, Inc. | Versartis, Inc. (NASDAQ: VSAR) | | 0 | | 2/13/2018 | Vaxart, Inc. | Aviragen Therapeutics, Inc. (NASDAQ: AVIR) | | 44 | | 1/30/2018 | Innovate Biopharmaceuticals, Inc. | Monster Digital, Inc. (NASDAQ: MSDI) | | 6 | | 1/17/2018 | Evofem Biosciences, Inc. | Neothetics, Inc. (NASDAQ: NEOT) | | 29 | | 1/4/2018 | Rocket Pharmaceuticals, Ltd | Inotek Pharmaceuticals Corp (NASDAQ: ITEK) | | 5 | …
Sonic Holdco, Inc.Evofem Biosciences, Inc.·S-4/A - Registration statement (business combination, amendment)·Q4 26·6 Nov
… of Cash ($M)** | | | 10/12/2018 | Aravive Biologics, Inc. | Versartis, Inc. (NASDAQ: VSAR) | | 0 | | 2/13/2018 | Vaxart, Inc. | Aviragen Therapeutics, Inc. (NASDAQ: AVIR) | | 44 | | 1/30/2018 | Innovate Biopharmaceuticals, Inc. | Monster Digital, Inc. (NASDAQ: MSDI) | | 6 | | 1/17/2018 | Evofem Biosciences, Inc. | Neothetics, Inc. (NASDAQ: NEOT) | | 29 | | 1/4/2018 | Rocket Pharmaceuticals, Ltd | Inotek Pharmaceuticals Corp (NASDAQ: ITEK) | | 5 | …
Boundless Bio, Inc.Evofem Biosciences, Inc.·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·3 Nov
… t of Cash ($M) | | | 10/12/2018 | Aravive Biologics, Inc. | Versartis, Inc. (NASDAQ: VSAR) | | 0 | | 2/13/2018 | Vaxart, Inc. | Aviragen Therapeutics, Inc. (NASDAQ: AVIR) | | 44 | | 1/30/2018 | Innovate Biopharmaceuticals, Inc. | Monster Digital, Inc. (NASDAQ: MSDI) | | 6 | | 1/17/2018 | Evofem Biosciences, Inc. | Neothetics, Inc. (NASDAQ: NEOT) | | 29 | | 1/4/2018 | Rocket Pharmaceuticals, Ltd | Inotek Pharmaceuticals Corp (NASDAQ: ITEK) | | 5 | …
Boundless Bio, Inc.Evofem Biosciences, Inc.·S-4/A - Registration statement (business combination, amendment)·Q4 26·30 Oct

Key Stats

Trading

Px/Chg 1D$0.01 / -5.13%

Avg Volume204.35K

Beta-0.28

Mkt Cap980.72K

FD Mkt Cap1.06M

Float

Shrs Out/Float132.53M / 132.53M

Short Float0.00%

Days to Cover1.00

Stock Repurchased$0.00

Current Valuation

EV55.98M

EV/EBITDA-18.98

EV/Sales2.77

P/B-0.01

P/S0.05

FCF Yield234.42%

ROE7.54%

ROA-73.70%

Current Ratio0.08

Estimates

P/E-0.16

Est P/E0.00

Est EPS-914.06

Est PEG0.00

Valuation

Metric	5Yr Avg	Jun '23	Mar '24	May '25	May '26	Oct '26
PRICE-BASED RATIOS
Price / Earnings	0.00	-0.01	0.00	-0.09	0.29	-0.18
Price / Sales	0.25	0.03	0.01	0.04	0.09	1.09
Price / Book Value	-0.01	-0.01	-0.00	-0.01	-0.01	-0.01
Price / Free Cash Flow	5.87	-0.01	-0.01	-0.21	29.15	0.43
ENTERPRISE VALUE METRICS
Enterprise Value	57.0	68.8	42.9	46.0	71.0	56.0
Enterprise Value / Sales	15.70	4.09	2.36	2.38	7.43	62.27
Enterprise Value / EBITDA	-0.47	-0.84	-2.67	-6.65	20.35	-12.56
Enterprise Value / EBIT	-0.05	-0.82	-2.40	-6.00	21.23	-12.25

Financials

Full Financials

Millions USD	5Yr CAGR (%)	Dec '21	Dec '22	Dec '23	Dec '24	Dec '25
INCOME STATEMENT
Revenue	25.1%	8.2	16.8	18.2	19.4	20.2
Gross Income	37.7%	4.2	12.4	11.7	15.5	15.1
EBITDA	—	-165.8	-82.1	-16.1	-6.9	2.1
EBIT	—	-166.8	-84.1	-17.8	-7.7	1.4
Net Income	—	-205.2	-76.7	53.0	-8.9	0.4
EPS (Diluted)	—	-2,962.49	-164.59	0.05	-0.09	0.00
BALANCE SHEET
Cash & ST Inv	-47.7%	7.7	2.8	0.6	0.7	0.6
Total Assets	-16.9%	42.5	25.2	10.6	23.8	20.3
Total Liabilities	-10.9%	142.1	97.0	77.1	95.0	89.7
Total Shareholder Equity	-8.6%	-99.6	-71.8	-66.5	-71.3	-69.4
CASH FLOW
Net Operating Cash Flow	-65.9%	-146.7	-70.4	-9.0	-3.9	-2.0
Cap Ex	-79.7%	-2.9	-0.3	-0.0	-0.0	-0.0
Free Cash Flow	-66%	-149.6	-70.8	-9.0	-3.9	-2.0

Enterprise Value Bridge

Millions USD		13 Nov '26
Price (As of 13 Nov '26)		0.01
Basic Shares		132.53
Market Cap		0.8
Diluted Shares		137.34
Fully Diluted Shares Outstanding		137.34
Fully Diluted Market Cap		0.9
+Consolidated Debt		68.5
−In-the-Money Convertible Debt		—
+Capital Leases		0.0
+Operating Leases		—
−Cash & Equivalents		-0.3
−Short-term Investments		-
+Total Preferred		5.0
−In-the-Money Convertible Preferred		—
−Investments in Unconsolidated Subs		—
+Non-Controlling Interest		-
+Pension Liabilities		—
Enterprise Value		74.1

Related companies